However, a number of studies over the past decade indicate that PDLIM1 is dysregulated in many tumors, such as hepatocellular carcinoma (HCC)9, colorectal cancer (CRC)10, gastric cancer (GC)11, ovarian cancer (OC)12, breast cancer13,14, glioblastoma15 and chronic myelogenous leukaemia (CML)16. Here, PDLIM1 is linked to hepatocellular carcinoma.